1. Home
  2. ONL vs ZNTL Comparison

ONL vs ZNTL Comparison

Compare ONL & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Orion Office REIT Inc.

ONL

Orion Office REIT Inc.

HOLD

Current Price

$2.09

Market Cap

111.5M

Sector

Real Estate

ML Signal

HOLD

Logo Zentalis Pharmaceuticals Inc.

ZNTL

Zentalis Pharmaceuticals Inc.

HOLD

Current Price

$2.87

Market Cap

118.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ONL
ZNTL
Founded
2021
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
111.5M
118.3M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
ONL
ZNTL
Price
$2.09
$2.87
Analyst Decision
Hold
Buy
Analyst Count
2
6
Target Price
N/A
$5.87
AVG Volume (30 Days)
255.9K
2.6M
Earning Date
03-05-2026
11-10-2025
Dividend Yield
3.72%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$149,775,000.00
$26,865,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.46
$1.01
52 Week High
$4.25
$3.95

Technical Indicators

Market Signals
Indicator
ONL
ZNTL
Relative Strength Index (RSI) 42.24 64.13
Support Level $2.04 $1.31
Resistance Level $2.20 $3.95
Average True Range (ATR) 0.09 0.38
MACD -0.01 0.09
Stochastic Oscillator 18.18 59.28

Price Performance

Historical Comparison
ONL
ZNTL

About ONL Orion Office REIT Inc.

Orion Properties Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased on a single-tenant net lease basis to creditworthy clients. The portfolio of the company includes traditional office buildings, governmental offices, medical offices, laboratories, and others. The Company operates in one business segment: direct ownership and operation of commercial real estate.

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Share on Social Networks: